Quinoa Protein Supplementation as a Novel Dietotherapy for Type 2 Diabetes Mellitus
DOI:
https://doi.org/10.54097/fz1xfq73Keywords:
T2DM, quinoa, dietotherapy, weight loss, diabetic nephropathy.Abstract
Type 2 Diabetes Mellitus (T2DM) is a metabolic disorder that affects the cardiovascular and urinary systems and characterized by high blood sugar levels. Current treatments have side effects and demand strict dietary control and exercise. Moreover, complications like diabetic nephropathy remain a major concern. In this study, we sought for a new dietotherapy for T2DM. Dietotherapy, a branch of dietetics concerned with therapeutic uses of food and diet, is receiving increasing attention in recent years due to food's dual roles in health and medical care. This study explores the potential of quinoa protein as a novel food-based approach for T2DM management and prevention. Chenopodium quinoa, known as the "superfood" or "golden grain," contains bioactive peptides with potential health benefits for metabolic disorders. However, its role on T2DM is not fully understood. This research investigates quinoa protein supplementation's anti-diabetic potential using physiological, histological, and cytological methods with C57BL/6 male mice and db/db diabetic mutants as animal models. This study provides evidence for the significant improvements that quinoa protein supplementation has on weight and glycemic control in both diabetic and healthy mice, offering restored peripheral insulin sensitivity as a biologically plausible explanation. Quinoa protein supplementation on mice also improved their kidney architecture, increased the number of glomeruli, and enhanced renal regularity, suggesting a protection against diabetic nephropathy. In short, this study revealed the potential of quinoa protein in weight loss, glucose control, and kidney protection. Scientific evidence are provided for further development of quinoa protein, which has a practical significance.
Downloads
References
E. Ahmad, S. Lim, R. Lamptey, D. R. Webb, and M. J. Davies, "Type 2 diabetes," (in eng), Lancet, vol. 400, no. 10365, pp. 1803-1820, Nov 19 2022.
(2023, September 14). Diabetes. Available: https://www.who.int/news-room/fact-sheets/detail/diabetes
Z. Liu, C. Fu, W. Wang, and B. Xu, "Prevalence of chronic complications of type 2 diabetes mellitus in outpatients - a cross-sectional hospital based survey in urban China," Health Qual Life Outcomes, vol. 8, p. 62, Jun 26 2010.
M. E. Lean et al., "Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial," Lancet, vol. 391, no. 10120, pp. 541-551, Feb 10 2018.
J. Upadhyay et al., "Pharmacotherapy of type 2 diabetes: An update," Metabolism, vol. 78, pp. 13-42, Jan 2018.
E. A. Martínez, F. F. Fuentes, and D. Bazile, "History of Quinoa: Its Origin, Domestication, Diversification, and Cultivation with Particular Reference to the Chilean Contex," Quinoa: Improvement and Sustainable Production, vol. 19, no. 24, 2015.
J. U. Obaroakpo et al., "The hyperglycemic regulatory effect of sprouted quinoa yoghurt in high-fat-diet and streptozotocin-induced type 2 diabetic mice via glucose and lipid homeostasis," (in eng), Food Funct, vol. 11, no. 9, pp. 8354-8368, Sep 23 2020.
T. Y. Wang et al., "Quinoa Reduces High-Fat Diet-Induced Obesity in Mice via Potential Microbiota-Gut-Brain-Liver Interaction Mechanisms," Microbiol Spectr, vol. 10, no. 3, p. e0032922, Jun 29 2022.
Y. Zhang, B. Bai, Y. Yan, J. Liang, and X. Guan, "Bound Polyphenols from Red Quinoa Prevailed over Free Polyphenols in Reducing Postprandial Blood Glucose Rises by Inhibiting α-Glucosidase Activity and Starch Digestion," (in eng), Nutrients, vol. 14, no. 4, Feb 9 2022.
D. Busso et al., "A Quinoa Protein Hydrolysate Fractionated by Electrodialysis with Ultrafiltration Membranes Improves Maternal and Fetal Outcomes in a Mouse Model of Gestational Diabetes Mellitus," (in eng), Mol Nutr Food Res, p. e2300047, Sep 4 2023.
M. E. Bowen, L. Xuan, I. Lingvay, and E. A. Halm, "Random blood glucose: a robust risk factor for type 2 diabetes," (in eng), J Clin Endocrinol Metab, vol. 100, no. 4, pp. 1503-10, Apr 2015.
Data is missing for average blood glucagon level of db/db-QPD as the remaining sample was insufficient for measurement
I. Caruso et al., "Glucagon in type 2 diabetes: Friend or foe?," (in eng), Diabetes Metab Res Rev, vol. 39, no. 3, p. e3609, Mar 2023.
A. Al Drees, M. Salah Khalil, and M. Soliman, "Histological and Immunohistochemical Basis of the Effect of Aminoguanidine on Renal Changes Associated with Hemorrhagic Shock in a Rat Model," (in eng), Acta Histochem Cytochem, vol. 50, no. 1, pp. 11-19, Feb 28 2017.
S. Dakhili, L. Abdolalizadeh, S. M. Hosseini, S. Shojaee-Aliabadi, and L. Mirmoghtadaie, "Quinoa protein: Composition, structure and functional properties," (in eng), Food Chem, vol. 299, p. 125161, Nov 30 2019.
F. Tang, Y. Hao, X. Zhang, and J. Qin, "Effect of echinacoside on kidney fibrosis by inhibition of TGF-β1/Smads signaling pathway in the db/db mice model of diabetic nephropathy," (in eng), Drug Des Devel Ther, vol. 11, pp. 2813-2826, 2017.
J. Guan, M. Wang, M. Zhao, W. Ni, and M. Zhang, "Discovery of Fibrinogen γ-chain as a potential urinary biomarker for renal interstitial fibrosis in IgA nephropathy," (in eng), BMC Nephrol, vol. 24, no. 1, p. 60, Mar 20 2023.
Data is missing for average blood glucagon level of db/db-QPD as the remaining sample was insufficient for measurement
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
